| scholarly article | Q13442814 |
| P50 | author | Stuart M Lichtman | Q56984320 |
| P2093 | author name string | Jasmeet Chadha Singh | |
| P2860 | cites work | High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller | Q24641848 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial | Q27853001 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 | ||
| The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia | Q28271441 | ||
| Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) | Q28291395 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status | Q30665329 | ||
| Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. | Q30870747 | ||
| Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials | Q33293618 | ||
| Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab | Q33930241 | ||
| Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials | Q34218132 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Age-specific changes in intrinsic breast cancer subtypes: a focus on older women | Q34359310 | ||
| Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | Q34484185 | ||
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer | Q35038093 | ||
| Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. | Q35170258 | ||
| The cardiotoxicity of chemotherapeutic drugs | Q35426013 | ||
| Trastuzumab and cardiac dysfunction: update on preclinical studies | Q35581800 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction | Q36116313 | ||
| ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. | Q36339400 | ||
| Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider | Q36339698 | ||
| Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer | Q36860669 | ||
| Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study | Q37038459 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics | Q37203741 | ||
| Cardiac toxicity of ErbB2-targeted therapies: what do we know? | Q37263119 | ||
| Trastuzumab-related cardiotoxicity among older patients with breast cancer | Q37289617 | ||
| Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). | Q37301426 | ||
| Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US | Q37390917 | ||
| Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience | Q37677684 | ||
| CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer | Q37819435 | ||
| Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. | Q38006133 | ||
| Cardiotoxicity of novel HER2-targeted therapies. | Q38108380 | ||
| Early and delayed clinical cardiotoxicity of doxorubicin | Q42225832 | ||
| Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy | Q42254236 | ||
| Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. | Q42626922 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | Q42677733 | ||
| Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab | Q42848146 | ||
| The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro | Q42910592 | ||
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 | ||
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. | Q43784378 | ||
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer | Q43937165 | ||
| Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm | Q44529239 | ||
| The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population | Q46659743 | ||
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial | Q47973074 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | Q53394493 | ||
| Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). | Q54346018 | ||
| Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. | Q54394851 | ||
| Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer | Q59567546 | ||
| Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre | Q61624905 | ||
| Cardiac side effects of trastuzumab: lessons learned from targeting cancer pathways | Q79888325 | ||
| Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience | Q80112164 | ||
| Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment | Q81419131 | ||
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Q87702640 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 975-982 | |
| P577 | publication date | 2015-12-08 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients | |
| P478 | volume | 32 |
Search more.